Cargando…
Clinical response to dabrafenib and chemotherapy in clonally-related histiocytosis and acute lymphoblastic leukemia
Autores principales: | Hubert, Gervaise, Bittencourt, Henrique, Laverdière, Caroline, Teira, Pierre, Cellot, Sonia, Langlois, Sylvie, Rouette, Alexandre, Sontag, Thomas, Sinnett, Daniel, Dal-Soglio, Dorothée, Turpin, Sophie, Tran, Thai Hoa |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Fondazione Ferrata Storti
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10230417/ https://www.ncbi.nlm.nih.gov/pubmed/36384252 http://dx.doi.org/10.3324/haematol.2022.281926 |
Ejemplares similares
-
Molecular Profiling of Hard-to-Treat Childhood and Adolescent Cancers
por: Khater, Fida, et al.
Publicado: (2019) -
Improvement of the Outcome of Relapsed or Refractory Acute Lymphoblastic Leukemia in Children Using a Risk-Based Treatment Strategy
por: Ceppi, Francesco, et al.
Publicado: (2016) -
Whole-transcriptome analysis in acute lymphoblastic leukemia: a report from the DFCI ALL Consortium Protocol 16-001
por: Tran, Thai Hoa, et al.
Publicado: (2022) -
Cutaneous Langerhans cell histiocytosis with gastrointestinal involvement treated with dabrafenib
por: Stewart, Jacob R., et al.
Publicado: (2017) -
Dabrafenib, alone or in combination with trametinib, in BRAF V600–mutated pediatric Langerhans cell histiocytosis
por: Whitlock, James A., et al.
Publicado: (2023)